Citigroup Inc Pulmonx Corp Transaction History

Citigroup Inc

$169 Billion
Q3 2024

A detailed history of Citigroup Inc transactions in Pulmonx Corp stock. As of the latest transaction made, Citigroup Inc holds 28,885 shares of LUNG stock, worth $183,130. This represents 0.0% of its overall portfolio holdings.

Number of Shares

28,885

Previous 8,418 243.13%

Holding current value

$183,130

Previous $53,000 350.94%

% of portfolio

0.0%

Previous 0.0%

13 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 12, 2024	BUY	$5.59 - $8.58 $114,410 - $175,606	20,467 Added 243.13%	28,885 $239,000
Q2 2024 Aug 12, 2024	BUY	$5.77 - $9.82 $12,220 - $20,798	2,118 Added 33.62%	8,418 $53,000
Q1 2024 May 10, 2024	BUY	$8.71 - $14.65 $8,553 - $14,386	982 Added 18.47%	6,300 $58,000
Q4 2023 Feb 09, 2024	BUY	$7.89 - $13.14 $39,868 - $66,396	5,053 Added 1906.79%	5,318 $67,000
Q3 2023 Nov 09, 2023	SELL	$9.88 - $14.0 $115,852 - $164,164	-11,726 Reduced 97.79%	265 $2,000
Q2 2023 Aug 10, 2023	SELL	$10.78 - $13.65 $560,603 - $709,854	-52,004 Reduced 81.26%	11,991 $157,000
Q1 2023 May 11, 2023	BUY	$7.49 - $12.54 $143,306 - $239,927	19,133 Added 42.65%	63,995 $715,000
Q4 2022 Feb 09, 2023	BUY	$4.92 - $17.35 $214,797 - $757,466	43,658 Added 3626.08%	44,862 $378,000
Q3 2022 Nov 10, 2022	SELL	$15.35 - $23.99 $25,066 - $39,175	-1,633 Reduced 57.56%	1,204 $20,000
Q2 2022 Aug 10, 2022	BUY	$14.0 - $27.95 $17,528 - $34,993	1,252 Added 78.99%	2,837 $42,000
Q1 2022 May 12, 2022	SELL	$21.13 - $35.65 $116,299 - $196,217	-5,504 Reduced 77.64%	1,585 $39,000
Q4 2021 Feb 10, 2022	BUY	$29.72 - $45.1 $92,072 - $139,719	3,098 Added 77.62%	7,089 $227,000
Q3 2021 Nov 10, 2021	BUY	$35.98 - $44.48 $143,596 - $177,519	3,991 New	3,991 $144,000

Others Institutions Holding LUNG

# of Institutions

123

Shares Held

31M

Call Options Held

300

Put Options Held

204K

View Full List

About Pulmonx Corp

Ticker LUNG
Exchange NASDAQ
Sector Healthcare
Industry Medical Devices
Shares Outstandng 37,268,400
Market Cap $236M
Description
Pulmonx Corporation, a medical technology company, provides minimally invasive devices for the treatment of chronic obstructive pulmonary diseases. It offers Zephyr Endobronchial Valve, a solution for the treatment of bronchoscopic in adult patients with hyperinflation associated with severe emphysema; and Chartis Pulmonary Assessment System, a ...

More about LUNG

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Citigroup Inc, based on Form 13F filings with the SEC.

News

Stay updated on Citigroup Inc with notifications on news.

Account